A Prospective, Single-arm, Multi-centre, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.
Phase of Trial: Phase IV
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Sirolimus (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Acronyms Morpheus
- Sponsors Meril Life Sciences
- 11 Apr 2018 Planned End Date changed from 1 May 2020 to 1 Dec 2020.
- 11 Apr 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2018.
- 11 Apr 2018 Status changed from not yet recruiting to recruiting.